Cargando…

Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment

One of the major limitations in the clinical use of existing oxazolidinone antibiotics is their characteristic adverse reactions, in particular thrombocytopenia. In anti-infective treatment, if patients are suspected of having drug-induced thrombocytopenia, the first step is to immediately discontin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bi, Liu, Ying, Luo, Jiaqi, Cai, Yun, Chen, Mengli, Wang, Tianlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165100/
https://www.ncbi.nlm.nih.gov/pubmed/37168994
http://dx.doi.org/10.3389/fphar.2023.1157437
_version_ 1785038197517975552
author Li, Bi
Liu, Ying
Luo, Jiaqi
Cai, Yun
Chen, Mengli
Wang, Tianlin
author_facet Li, Bi
Liu, Ying
Luo, Jiaqi
Cai, Yun
Chen, Mengli
Wang, Tianlin
author_sort Li, Bi
collection PubMed
description One of the major limitations in the clinical use of existing oxazolidinone antibiotics is their characteristic adverse reactions, in particular thrombocytopenia. In anti-infective treatment, if patients are suspected of having drug-induced thrombocytopenia, the first step is to immediately discontinue the offending drug. Even in patients with severe infections, the antibacterial drug may need to be changed or the antibacterial treatment may need to be discontinued because thrombocytopenia may have a more serious clinical prognosis. In addition, if the patient needs to continue antibacterial treatment after discharge, the lack of conditions for monitoring platelet levels may also pose hidden dangers to the patient. Contezolid is an orally administered oxazolidinone antibacterial agent approved by the National Medical Products Administration of China in 2021. We found that contezolid may have an improved safety profile with a significantly reduced potential for myelosuppression based on the results of our observational clinical study. In this article, we review the advantages of contezolid as a new oxazolidinone antibiotic and describe three typical clinical cases of patients who experienced drug-induced thrombocytopenia after using linezolid. The platelet levels of these different patients were all significantly improved to varying degrees after initiation of contezolid treatment.
format Online
Article
Text
id pubmed-10165100
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101651002023-05-09 Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment Li, Bi Liu, Ying Luo, Jiaqi Cai, Yun Chen, Mengli Wang, Tianlin Front Pharmacol Pharmacology One of the major limitations in the clinical use of existing oxazolidinone antibiotics is their characteristic adverse reactions, in particular thrombocytopenia. In anti-infective treatment, if patients are suspected of having drug-induced thrombocytopenia, the first step is to immediately discontinue the offending drug. Even in patients with severe infections, the antibacterial drug may need to be changed or the antibacterial treatment may need to be discontinued because thrombocytopenia may have a more serious clinical prognosis. In addition, if the patient needs to continue antibacterial treatment after discharge, the lack of conditions for monitoring platelet levels may also pose hidden dangers to the patient. Contezolid is an orally administered oxazolidinone antibacterial agent approved by the National Medical Products Administration of China in 2021. We found that contezolid may have an improved safety profile with a significantly reduced potential for myelosuppression based on the results of our observational clinical study. In this article, we review the advantages of contezolid as a new oxazolidinone antibiotic and describe three typical clinical cases of patients who experienced drug-induced thrombocytopenia after using linezolid. The platelet levels of these different patients were all significantly improved to varying degrees after initiation of contezolid treatment. Frontiers Media S.A. 2023-04-24 /pmc/articles/PMC10165100/ /pubmed/37168994 http://dx.doi.org/10.3389/fphar.2023.1157437 Text en Copyright © 2023 Li, Liu, Luo, Cai, Chen and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Bi
Liu, Ying
Luo, Jiaqi
Cai, Yun
Chen, Mengli
Wang, Tianlin
Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
title Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
title_full Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
title_fullStr Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
title_full_unstemmed Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
title_short Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
title_sort contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165100/
https://www.ncbi.nlm.nih.gov/pubmed/37168994
http://dx.doi.org/10.3389/fphar.2023.1157437
work_keys_str_mv AT libi contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment
AT liuying contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment
AT luojiaqi contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment
AT caiyun contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment
AT chenmengli contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment
AT wangtianlin contezolidanoveloxazolidinoneantibioticmayimprovedrugrelatedthrombocytopeniainclinicalantibacterialtreatment